From a Pioneer in hydrogel patches to an Innovation Leader in systemic transdermal products
Patch Medication, Globally.
Teikoku Seiyaku is a pioneer in the field of anti-inflammatory hydrogel patches, succeeding in developing the first hot sensation hydrogel patch and the first topical external hydrogel patch containing anti-inflammatory and analgesic drugs which are delivered by absorption through the skin.
Although we may assume that medicine is generally taken through the mouth, depending on the nature of the medicine, absorption through the skin may be more efficient and cause fewer side effects than taking medicine orally.
In addition, active ingredients can be absorbed through the skin, making patches easier to use for the elderly and other patients, as well as making it easier to confirm whether the medication has been taken or not.
In 2022, “ALLYDONE® Patches” (donepezil transdermal patches) for mild to severe Alzheimer’s disease were approved as a new drug in Japan.
Teikoku Seiyaku, with its unique ideas and technological capabilities, will deliver products to the world that can contribute to society by carefully identifying the needs of the times.
- ※Plaster production volume is approximately 7,500 tons per year. Approximately 500 million pieces each 10cm x 14cm in size (actual production in 2023)
Hot Sensation Hydrogel Patch *
(Approved in Japan on September 28, 1977)
Indomethacin Medicated Hydrogel Patch *
(Approved in Japan on March 29, 1988)
Felbinac Medicated Hydrogel Patch*
(Approved in Japan on July 2, 1993)
Lidocaine Medicated Hydrogel Patch **
(Approved in the US on March 19, 1999)
*Original packaging **Not sold in Japan